Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posterior chamber phakic intraocular lens implantation in keratoconic eyes: long-term changes in visual acuity

Search Title by author or title

Session Details

Session Title: Keratoconus and Phakic IOLs

Session Date/Time: Monday 12/09/2016 | 16:30-18:30

Paper Time: 17:57

Venue: Hall C4

First Author: : D.Badoza ARGENTINA

Co Author(s): :    E. Benitez Saldivar   S. Ambrosetto   M. Cosentino              

Abstract Details

Purpose:

To evaluate long-term evolution of visual acuity (VA) after posterior-chamber phakic intraocular lens implantation in keratoconic eyes

Setting:

Instituto de la Visión, Buenos Aires, Argentina

Methods:

We retrospectively studied 18 eyes of 11 patients with keratoconus in which Visian Toric ICL was implanted. Age was 37.8 ±12.2 years-old. We analyzed evolution of refraction and VA at 1 month, 1 year, 2 years, and 3 years.

Results:

Preoperative sphere, was -7.1±5.7D and cylinder was -4.2±1.5D; Uncorrected Visual Acuity (UCVA) was less than 20/70 in 100% of the cases, whereas Best Corrected Visual Acuity (BCVA) was 20/40 or better in 6 eyes (33.3%). Follow-up was 26.3±10.3 months. At postoperative first month, sphere and cylinder were 0.00±0.91D and -0.8±1.5D, respectively. No statistically significant differences in following examinations were found. UCVA was 20/40 or better in 55.5% at month 1, in 72.2% at year 2, and in 66.6% at year 3. No case had lost lines of BCVA, and 2.0±1.4 lines of VA were gained at month 1, comparing with 2.6±1.6 at year 3. Efficacy and Safety Indexes were 1.45 and 1.69, respectively

Conclusions:

Implantation of posterior-chamber phakic intraocular lens in eyes with keratoconus is an effective and safe procedure. Additionally, in some cases, improvement of both UCVA and BCVA continues on long term follow-up.

Financial Disclosure:

NONE

Back to previous